Clinic-based infant screening for duchenne muscular dystrophy: A feasibility study

PLoS Currents

Volumn , Issue , 2012, Pages

  Cyrus, Alissa ^a   Street, Natalie ^a   Quary, Sharon ^b   Kable, Julie ^c   Kenneson, Aileen ^d   Fernhoff, Paul ^c  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b Newborn Screening Unit   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SYRACUSE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ATTITUDE; DIAGNOSTIC ACCURACY; DUCHENNE MUSCULAR DYSTROPHY; FEASIBILITY STUDY; HEALTH CARE PERSONNEL; HUMAN; INFANT; INFANT SCREENING; MAJOR CLINICAL STUDY; MALE; PEDIATRIC HOSPITAL; QUESTIONNAIRE; SCREENING; CHILD; CHILD PARENT RELATION; HEALTH SERVICE; PRESCHOOL CHILD; SCREENING TEST; BLOOD SAMPLING; PARENT; PARENTAL CONSENT; TWINS;

CREATINE KINASE;

EID: 84867436953     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/4f99c5654147a     Document Type: Article

References (36)

1. Bradley D, Parsons E. Newborn screening for Duchenne muscular dystrophy. Semin Neonatal. 1998;3:27-34.
2. Drousiotou A, Ioannou P, Georgiou T, et al. Neonatal screening for Duchenne muscular dystrophy: a novel semiquantitative application of the bioluminescence test for creatine kinase in a pilot national program in Cyprus. Genet Test. 1998;2(1):55-60.
3. Emery AE. Duchenne Muscular Dystrophy. 2nd ed. New York: Oxford University Press; 1987.
4. Ciafaloni E, Fox DJ, Pandya S, et al. Delayed diagnosis in Duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr. Sep 2009;155:380-385.
5. Crisp DE, Ziter FA, Bray PF. Diagnostic delay in Duchenne's muscular dystrophy. JAMA. Jan 22-29 1982;247:478-480.
6. Mohamed K, Appleton R, Nicolaides P. Delayed diagnosis of Duchenne muscular dystrophy. Eur J Paediatr Neurol. 2000;4:219-223.
7. Marshall PD, Galasko CS. No improvement in delay in diagnosis of Duchenne muscular dystrophy [letter]. Lancet. Vol 345. 1995/03/04 ed1995:590-591.
8. Scheuerbrandt G, Lundin A, Lovgren T, Mortier W. Screening for Duchenne muscular dystrophy: an improved screening test for creatine kinase and its application in an infant screening program. Muscle Nerve. Jan 1986;9:11-23.
9. van Ommen GJ, Scheuerbrandt G. Neonatal screening for muscular dystrophy. Consensus recommendation of the 14th workshop sponsored by the European Neuromuscular Center (ENMC). Neuromuscul Disord. May 1993;3:231-239.
10. Zellweger H, Antonik A. Newborn screening for Duchenne muscular dystrophy. Pediatrics. Jan 1975;55:30-34.
11. Drummond LM. Creatine phosphokinase levels in the newborn and their use in screening for Duchenne muscular dystrophy. Arch Dis Child. May 1979;54(5):362-366.
12. Plauchu H, Cordier MP, Carrier HN, et al. Systematic neonatal detection of Duchenne's muscular dystrophy. Results after 10 years' of experience in Lyons (France). J Genet Hum. Aug 1987;35(4):217-230.
13. Skinner R, Emery AE, Scheuerbrandt G, Syme J. Feasibility of neonatal screening for Duchenne muscular dystrophy. J Med Genet. Feb 1982;19(1):1-3.
14. Eyskens F, Philips E. Newborn screening for Duchenne muscular dystrophy. The experience in the province of Antwerp. Neuromuscular Disorders. 2006;16:721.
15. Greenberg CR, Jacobs HK, Halliday W, Wrogemann K. Three years' experience with neonatal screening for Duchenne/Becker muscular dystrophy: gene analysis, gene expression, and phenotype prediction. Am J Med Genet. Apr 1 1991;39(1):68-75.
16. Naylor E, Hoffman E, Paulus-Thomas J, et al. Neonatal screening for Duchenne/Becker muscular dystrophy: reconsideration based on molecular diagnosis and potential therapeutics. Screening. 1992;1:99-113.
17. Wilson JM, Jungner YG. Principles and practice of screening for disease. Public Health Papers. no. 34. Geneva: World Health Organization. 1968:163p.
18. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. Jan 2010;9:77-93.
19. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. Feb 2010;9:177-189.
20. Moxley RT, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. Jan 11 2005;64:13-20.
21. American Academy of Pediatrics Section on Cardiology and Cardiac Surgery. Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. Pediatrics. Dec 2005;116:1569-1573.
22. Finder JD, Birnkrant D, Carl J, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med. Aug 15 2004;170(4):456-465.
23. Ross LF. Screening for conditions that do not meet the Wilson and Jungner criteria: the case of Duchenne muscular dystrophy. Am J Med Genet A. Apr 15 2006;140:914-922.
24. American Society of Human Genetics (ASHG) American College of Medical Genetics (ACMG). Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet. Nov 1995;57:1233-1241.
25. Hewlett J, Waisbren SE. A review of the psychosocial effects of false-positive results on parents and current communication practices in newborn screening. J Inherit Metab Dis. Oct 2006;29:677-682.
26. Fuentes-Afflick E, Hessol NA. Interpregnancy interval and the risk of premature infants. Obstet Gynecol. Mar 2000;95:383-390.
27. Mendell JR, Shilling C, Leslie ND, et al. Evidence-based path to newborn screening for duchenne muscular dystrophy. Annals of neurology. Mar 2012;71(3):304-313.
28. Orfanos AP, Naylor EW. A rapid screening test for Duchenne muscular dystrophy using dried blood specimens. Clin Chim Acta. Apr 27 1984;138:267-274.
29. American Academy of Pediatrics Committee on Nutrition. Iron fortification of infant formulas. Pediatrics. Jul 1999;104:119-123.
30. Statistical Package for the Social Sciences (SPSS) [computer program]. Version 15.0. Chicago, IL: SPSS, Inc.; 2006.
31. Blum D, Brauman J. Serum enzymes in the neonatal period. Diagnostic aid in muscle pathology. Biol Neonate. 1975;26(1-2):53-57.
32. Bailey DB, Jr., Beskow LM, Davis AM, Skinner D. Changing perspectives on the benefits of newborn screening. Ment Retard Dev Disabil Res Rev. 2006;12:270-279.
33. Grosse SD, Boyle CA, Kenneson A, Khoury MJ, Wilfond BS. From public health emergency to public health service: the implications of evolving criteria for newborn screening panels. Pediatrics. Mar 2006;117:923-929.
34. American College of Medical Genetics Newborn Screening Expert Group. Newborn screening: toward a uniform screening panel and system--executive summary. Pediatrics. May 2006;117:S296-307.
35. Calonge N, Green NS, Rinaldo P, et al. Committee report: Method for evaluating conditions nominated for population-based screening of newborns and children. Genet Med. Mar 2010;12(3):153-159.
36. Kemper AR, Bailey DB, Jr. Pediatricians' knowledge of and attitudes toward fragile X syndrome screening. Acad Pediatr. Mar-Apr 2009;9:114-117.